NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $0.36 -0.04 (-9.90%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Onconetix Stock (NASDAQ:ONCO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Onconetix alerts:Sign Up Key Stats Today's Range$0.36▼$0.4050-Day Range$0.40▼$3.6152-Week Range$0.36▼$74.29Volume404,040 shsAverage Volume5.38 million shsMarket Capitalization$238.78 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingOnconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageOnconetix has only been the subject of 1 research reports in the past 90 days.Read more about Onconetix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconetix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconetix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted34.99% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 66.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Onconetix this week, compared to 1 article on an average week.Search Interest20 people have searched for ONCO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Onconetix to their MarketBeat watchlist in the last 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $8,406.00 in company stock, which represents 3.3810% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have bought 5.82% more of their company's stock than they have sold. Specifically, they have bought $152,875.00 in company stock and sold $144,469.00 in company stock.Percentage Held by Insiders0.27% of the stock of Onconetix is held by insiders.Percentage Held by Institutions23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCO Stock News HeadlinesOnconetix Shareholders Approve Flexible Reverse Stock Split Authorization4 hours ago | theglobeandmail.comWall Street Zen Upgrades Onconetix (NASDAQ:ONCO) to "Hold"May 2, 2026 | americanbankingnews.comThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software stocks two months before they crashed this year. Now, he's warning that one AI lab's breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He's found a little-known $40 "pre-IPO backdoor" into the private startup behind this economic sea change.May 8 at 1:00 AM | Chaikin Analytics (Ad)Onconetix Reshapes Board Leadership With New Chairman, DirectorApril 24, 2026 | tipranks.comOnconetix: HRT financial, 10% owner, sells $110,169 in stockApril 23, 2026 | investing.comInsider Selling: Onconetix (NASDAQ:ONCO) Major Shareholder Sells 49,710 Shares of StockApril 23, 2026 | insidertrades.comOnconetix (NASDAQ:ONCO) Major Shareholder Acquires $25,284.28 in StockApril 22, 2026 | insidertrades.comOnconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Buys 74,350 SharesApril 17, 2026 | insidertrades.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $7.80 at the start of the year. Since then, ONCO stock has decreased by 95.3% and is now trading at $0.37. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) released its quarterly earnings results on Thursday, November, 13th. The company reported ($31.25) EPS for the quarter. The company had revenue of $0.30 million for the quarter. Onconetix had a positive trailing twelve-month return on equity of 8.24% and a negative net margin of 1,717.50%. When did Onconetix's stock split? Onconetix shares reverse split on the morning of Wednesday, March 25th 2026.The 1-5 reverse split was announced on Monday, March 23rd 2026. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 24th 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Onconetix IPO? Onconetix (ONCO) raised $20 million in an initial public offering on Thursday, February 17th 2022. The company issued 2,222,222 shares at $8.00-$10.00 per share. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include Qualcomm (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings11/13/2025Today5/08/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ONCO's financial health is in the Red zone, according to TradeSmith. ONCO has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)($216.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.03 million Net Margins-1,717.50% Pretax Margin-1,721.72% Return on Equity8.24% Return on Assets2.90% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.65 Sales & Book Value Annual Sales$815.37 thousand Price / Sales0.29 Cash FlowN/A Price / Cash FlowN/A Book Value$50.53 per share Price / Book0.01Miscellaneous Outstanding Shares656,000Free Float654,000Market Cap$238.78 thousand OptionableN/A Beta3.01 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ONCO) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
